More Than Fibrosis: The Biology and Prognostic Power of Liver Stiffness, Part 2

This joint educational session of the Autoimmune and Cholestatic Liver Disease and Fibrosis Special Interest Groups examines liver stiffness as a unifying concept linking fibrosis, immune-mediated injury, and clinical outcomes across autoimmune, cholestatic, and metabolic liver diseases.   Part 1 focuses on the mechanistic foundations of liver stiffness, highlighting how extracellular matrix composition and collagen organization, mechanical forces within the liver microenvironment, and cellular mechanosensing and mechanotransduction pathways can influence hepatic cell behavior and disease progression. The session also explores emerging evidence of a stiffness-driven signaling contribution to fibrogenesis as well as immune activation and hepatocellular carcinoma risk, underscoring the role of mechanobiology in chronic immune-mediated and cholestatic liver disease.   Part 2 emphasizes the physiologic and clinical interpretation of liver stiffness, addressing how vascular flow, portal pressure, inflammation, and cholangiocyte-specific biology influence stiffness measurements obtained through noninvasive modalities. The session also explores how liver stiffness can predict clinical outcomes in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, and how insights from murine models of cholangiopathy inform both disease mechanisms and biomarker interpretation in human disease.   Together, these sessions provide learners with a cohesive framework for understanding liver stiffness beyond fibrosis alone, integrating mechanistic biology with clinical applications. Attendees will leave with a clearer appreciation of how liver stiffness reflects dynamic pathophysiologic processes, how it can be used to stratify risk and prognosis in autoimmune and cholestatic liver disease, and why it has become an increasingly important tool in the management of liver diseases.